Nanoviricides Inc (NNVC) 2.97 $NNVC
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
NanoViricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats Performed by BASi
PR Newswire - Fri Jan 23, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reported a good safety profile of an optimized FluCide® drug candidate in a GLP-like toxicology study in rats. These results are extremely important since they indicate that FluCide continues to look very promising as one of the most advanced candidates in the Company's drug development pipeline.
NNVC: 2.97 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:45AM CST
HSGX: 8.61 (-0.07), CRIS: 3.23 (+0.25), NES: 3.52 (+0.13), TZOO: 9.88 (+0.49), WLT: 1.09 (+0.05), FXCM: 2.21 (-0.01), NNVC: 2.97 (-0.05), VLTC: 0.77 (-0.04), CYN: 90.32 (+0.49), ANR: 1.27 (+0.03), OTIC: 31.14 (+0.13), MHR: 2.62 (+0.11), EGLT: 10.60 (+0.58), NERV: 4.68 (+0.09), FFIV: 116.64 (+1.37), KEG: 2.14 (+0.08), CTP: 6.53 (+0.13), ENRJ: 2.81 (+0.06), LE: 35.84 (+0.19)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
PR Newswire - Thu Jan 22, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , a nanomedicine company developing anti-viral drugs, reported that it has shipped several anti-Ebola nanoviricide® drug candidates to a hi-security bio-containment facility in the US that is capable of performing evaluation of these drug candidates in the required biological safety level 4 (BSL-4) environment.
NNVC: 2.97 (-0.05)
NanoViricides announces purchase of common stock by insiders
M2 - Thu Jan 22, 5:29AM CST
Nanomaterials antiviral company NanoViricides (NYSE MKT:NNVC) said on Wednesday that its executives purchased 62,392 shares of its common stock in uncoordinated open market purchases during its open trading windows for insiders.
NNVC: 2.97 (-0.05)
NanoViricides, Inc.'s Executive Officers Report Insider Purchases of Common Stock
PR Newswire - Wed Jan 21, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , reported that between January 6 and 13, 2015, Anil Diwan, PhD, the Company's co-founder, President and Chairman, and Dr. Milton Boniuk, an independent member of the Board of Directors, separately purchased NanoViricides common stock in open market purchases, during one of the Company's open trading windows for insiders.
NNVC: 2.97 (-0.05)
InsiderInsights.com Daily Round Up For 1/13/15: TWTR, WIW, STZ, ALL
InsiderInsights - at Seeking Alpha - Thu Jan 15, 8:54AM CST
STRM: 4.07 (+0.04), STZ: 113.03 (-0.48), CRDS: 2.32 (+0.05), PETX: 16.52 (-0.10), NNVC: 2.97 (-0.05), RM: 15.88 (+0.96), ALL: 71.46 (-0.11), TNET: 36.49 (+0.76), SFST: 17.20 (-0.42), AGEN: 5.03 (-0.01), GES: 19.01 (+0.49), WIW: 11.29 (unch), LRCX: 82.21 (+1.10), COST: 147.10 (-0.66), EBF: 13.90 (+0.02), TWTR: 48.50 (+0.55), JGW: 10.70 (-0.16), WIA: 11.49 (-0.03)
InsiderInsights.com Daily Round Up 1/12/15: BH, LTS, OPK, SNCR
InsiderInsights - at Seeking Alpha - Tue Jan 13, 9:51AM CST
AFAM: 30.88 (+0.37), RTN: 107.03 (-0.37), AERI: 27.91 (+0.14), MRD: 18.66 (+0.23), ADX: 14.08 (+0.11), LTS: 3.92 (-0.02), NNVC: 2.97 (-0.05), ARDX: 17.14 (+0.71), PANW: 135.27 (+2.26), CTRE: 13.46 (+0.26), PCTY: 28.59 (+0.38), BH: 416.41 (-1.55), WIW: 11.29 (unch), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), UBA: 22.84 (-0.21), WIA: 11.49 (-0.03)
NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility
PR Newswire - Wed Jan 07, 6:30AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , has completed the purchase of the state of the art cGMP-compliant Manufacturing and R&D facility located in Shelton, Connecticut, from Inno-Haven, LLC.
NNVC: 2.97 (-0.05)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.01 (-0.01), NNVC: 2.97 (-0.05)
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), PLX: 1.84 (-0.04), NLNK: 38.84 (+1.51), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
NanoViricides Says Injectable FluCide(TM) Selected in Top Ten Project to Watch - Presentation Today at the Therapeutics Area Partnerships Meeting in Boston
Business Wire - Thu Nov 20, 1:15AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , announced today that its "Injectable FluCide(TM)" drug candidate for severe influenza has been chosen as one of the "Top Ten Infectious Diseases Projects to Watch" by a panel of industry experts assembled by Informa and the publishers of In Vivo, Startup and The Pink Sheet. As a result of this selection, Anil R. Diwan, PhD, President and Chairman of the Company, will give a company presentation at the Therapeutic Area Partnerships Meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston (www.tapartnerships.com). The presentation is scheduled for 4:20pm Eastern time, today, November 20, 2014.
NNVC: 2.97 (-0.05)
NanoViricides CEO, Eugene Seymour, MD, MPH, Invited to Discuss the Current Ebola Outbreak on Fox Business News at 9PM EDT Tonight
Business Wire - Tue Nov 18, 1:58AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH, has been invited to discuss the current Ebola outbreak and the Company's progress on a novel experimental Ebola drug on "The Independents", a show on the Fox Business News Channel (FBN) at 9PM EDT tonight, November 18th.
NNVC: 2.97 (-0.05)
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:06AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), NLNK: 38.84 (+1.51), PLX: 1.84 (-0.04), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
NanoViricides net loss improves in FQ1
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:20AM CST
NNVC: 2.97 (-0.05)
NanoViricides beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:12AM CST
NNVC: 2.97 (-0.05)
NanoViricides, Inc. Files Quarterly Report - Reports Further Improved Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates
Business Wire - Mon Nov 17, 6:01AM CST
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" , has filed its quarterly report with the Securities and Exchange Commission on Friday, November 14th, in a timely fashion. The submission can be downloaded from the SEC website at http://www.sec.gov/Archives/edgar/data/137900...-index.htm
NNVC: 2.97 (-0.05)
Update: NanoViricides Earnings Filings Warn Of Delays, Delays, And More Delays
The Specialist - at Seeking Alpha - Sun Nov 16, 11:47PM CST
NNVC: 2.97 (-0.05)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 6.80 (-0.15), JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
NanoViricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats Performed by BASi
PR Newswire - Fri Jan 23, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reported a good safety profile of an optimized FluCide® drug candidate in a GLP-like toxicology study in rats. These results are extremely important since they indicate that FluCide continues to look very promising as one of the most advanced candidates in the Company's drug development pipeline. NNVC: 2.97 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:45AM CST
HSGX: 8.61 (-0.07), CRIS: 3.23 (+0.25), NES: 3.52 (+0.13), TZOO: 9.88 (+0.49), WLT: 1.09 (+0.05), FXCM: 2.21 (-0.01), NNVC: 2.97 (-0.05), VLTC: 0.77 (-0.04), CYN: 90.32 (+0.49), ANR: 1.27 (+0.03), OTIC: 31.14 (+0.13), MHR: 2.62 (+0.11), EGLT: 10.60 (+0.58), NERV: 4.68 (+0.09), FFIV: 116.64 (+1.37), KEG: 2.14 (+0.08), CTP: 6.53 (+0.13), ENRJ: 2.81 (+0.06), LE: 35.84 (+0.19)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
PR Newswire - Thu Jan 22, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reported that it has shipped several anti-Ebola nanoviricide® drug candidates to a hi-security bio-containment facility in the US that is capable of performing evaluation of these drug candidates in the required biological safety level 4 (BSL-4) environment. NNVC: 2.97 (-0.05)
NanoViricides announces purchase of common stock by insiders
M2 - Thu Jan 22, 5:29AM CST
Nanomaterials antiviral company NanoViricides (NYSE MKT:NNVC) said on Wednesday that its executives purchased 62,392 shares of its common stock in uncoordinated open market purchases during its open trading windows for insiders.
NNVC: 2.97 (-0.05)
NanoViricides, Inc.'s Executive Officers Report Insider Purchases of Common Stock
PR Newswire - Wed Jan 21, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, reported that between January 6 and 13, 2015, Anil Diwan, PhD, the Company's co-founder, President and Chairman, and Dr. Milton Boniuk, an independent member of the Board of Directors, separately purchased NanoViricides common stock in open market purchases, during one of the Company's open trading windows for insiders. NNVC: 2.97 (-0.05)
InsiderInsights.com Daily Round Up For 1/13/15: TWTR, WIW, STZ, ALL
InsiderInsights - at Seeking Alpha - Thu Jan 15, 8:54AM CST
STRM: 4.07 (+0.04), STZ: 113.03 (-0.48), CRDS: 2.32 (+0.05), PETX: 16.52 (-0.10), NNVC: 2.97 (-0.05), RM: 15.88 (+0.96), ALL: 71.46 (-0.11), TNET: 36.49 (+0.76), SFST: 17.20 (-0.42), AGEN: 5.03 (-0.01), GES: 19.01 (+0.49), WIW: 11.29 (unch), LRCX: 82.21 (+1.10), COST: 147.10 (-0.66), EBF: 13.90 (+0.02), TWTR: 48.50 (+0.55), JGW: 10.70 (-0.16), WIA: 11.49 (-0.03)
InsiderInsights.com Daily Round Up 1/12/15: BH, LTS, OPK, SNCR
InsiderInsights - at Seeking Alpha - Tue Jan 13, 9:51AM CST
AFAM: 30.88 (+0.37), RTN: 107.03 (-0.37), AERI: 27.91 (+0.14), MRD: 18.66 (+0.23), ADX: 14.08 (+0.11), LTS: 3.92 (-0.02), NNVC: 2.97 (-0.05), ARDX: 17.14 (+0.71), PANW: 135.27 (+2.26), CTRE: 13.46 (+0.26), PCTY: 28.59 (+0.38), BH: 416.41 (-1.55), WIW: 11.29 (unch), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), UBA: 22.84 (-0.21), WIA: 11.49 (-0.03)
NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility
PR Newswire - Wed Jan 07, 6:30AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, has completed the purchase of the state of the art cGMP-compliant Manufacturing and R&D facility located in Shelton, Connecticut, from Inno-Haven, LLC. NNVC: 2.97 (-0.05)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.01 (-0.01), NNVC: 2.97 (-0.05)
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), PLX: 1.84 (-0.04), NLNK: 38.84 (+1.51), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
NanoViricides Says Injectable FluCide(TM) Selected in Top Ten Project to Watch - Presentation Today at the Therapeutics Area Partnerships Meeting in Boston
Business Wire - Thu Nov 20, 1:15AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, announced today that its "Injectable FluCide(TM)" drug candidate for severe influenza has been chosen as one of the "Top Ten Infectious Diseases Projects to Watch" by a panel of industry experts assembled by Informa and the publishers of In Vivo, Startup and The Pink Sheet. As a result of this selection, Anil R. Diwan, PhD, President and Chairman of the Company, will give a company presentation at the Therapeutic Area Partnerships Meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston (www.tapartnerships.com). The presentation is scheduled for 4:20pm Eastern time, today, November 20, 2014. NNVC: 2.97 (-0.05)
NanoViricides CEO, Eugene Seymour, MD, MPH, Invited to Discuss the Current Ebola Outbreak on Fox Business News at 9PM EDT Tonight
Business Wire - Tue Nov 18, 1:58AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH, has been invited to discuss the current Ebola outbreak and the Company's progress on a novel experimental Ebola drug on "The Independents", a show on the Fox Business News Channel (FBN) at 9PM EDT tonight, November 18th. NNVC: 2.97 (-0.05)
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:06AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), NLNK: 38.84 (+1.51), PLX: 1.84 (-0.04), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
NanoViricides net loss improves in FQ1
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:20AM CST
NNVC: 2.97 (-0.05)
NanoViricides beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:12AM CST
NNVC: 2.97 (-0.05)
NanoViricides, Inc. Files Quarterly Report - Reports Further Improved Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates
Business Wire - Mon Nov 17, 6:01AM CST
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"
, has filed its quarterly report with the Securities and Exchange Commission on Friday, November 14th, in a timely fashion. The submission can be downloaded from the SEC website at http://www.sec.gov/Archives/edgar/data/137900...-index.htm NNVC: 2.97 (-0.05)
Update: NanoViricides Earnings Filings Warn Of Delays, Delays, And More Delays
The Specialist - at Seeking Alpha - Sun Nov 16, 11:47PM CST
NNVC: 2.97 (-0.05)
